Divi's Labs consolidated PAT surges 64% YoY to ₹1,127 Cr, margins hit record 42.6%
PAT +63.6% YoY · revenue +35.4% · margins expanding · beat vs street
₹3,676 Cr
+35.4% YoY
₹1,127 Cr
+63.6% YoY
29.89%
+5.8pp YoY
₹42.49
Divi's Laboratories posted consolidated total income of ₹3,770 Cr for Q2 FY27, with revenue from operations up 35.4% YoY (and 19.4% QoQ) to ₹3,676 Cr, and PAT up 63.6% YoY (24.9% QoQ) to ₹1,127 Cr. The print clears the pre-result preview's on-plan range on every count: revenue (₹3,100–3,200 Cr expected vs ₹3,676 Cr actual), EBITDA margin (38–41% expected vs ~42.6% actual) and PAT (₹800–900 Cr expected vs ₹1,127 Cr actual) — resolving the Street's Q1-era debate (level-change vs peak) in favour of a level change, at least for this quarter. It also clears management's own August guidance of "double-digit FY27 revenue growth" and EBITDA "similar to FY26" by a wide margin — FY26's full-year EBITDA margin ran near 32–33%, roughly 10 percentage points below this quarter's print.
Q2 FY-2027 vs prior quarters
The margin expansion is broad-based rather than a single line item: gross margin (revenue less material cost and inventory movement) works out to roughly 68%, well above the ~60% management flagged for the year, helped by a ₹631 Cr build in finished-goods/WIP inventory that reduced the reported cost-of-materials line. EBITDA margin (OPM) expanded to ~42.6% from 32.7% a year ago and 40.8% last quarter, while net margin improved to 29.9% from 24.1% YoY and 28.7% QoQ — both metrics trending up sequentially for a second straight quarter, not just a one-off pop.
The stock went into the print at ₹10,320.5, up 7.6% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
No exceptional items this quarter (unlike FY26's full-year ₹74 Cr labour-code impact), so growth is on a clean base
FY27 double-digit revenue growth assured. Gross margin ~60% all year, EBITDA similar to FY26. Three major capex projects ~70% capitalized (₹1400 Cr of ₹2000 Cr); timelines dependent on customer regulatory approvals. 18-20 projects commercialized or in commercialization.
— This quarter: beat
H1 FY27 consolidated PAT stands at ₹2,029 Cr on revenue of ₹6,756 Cr, up 64.5% and 31.8% respectively over H1 FY26, confirming this isn't a single-quarter anomaly after Q1's similarly strong ₹902 Cr PAT (+66% YoY, per the prior release). Standalone tracks consolidated closely (PAT ₹1,140 Cr, +63.8% YoY), so there's no meaningful standalone-vs-consolidated story to flag. The company's own press release is a factual recap of the total income/PBT/PAT figures with no incremental qualitative commentary on drivers or outlook beyond what was already said on the August concall; the board otherwise used the November 7 meeting only to approve the results and press release, with no other business items disclosed in this filing.
W1
Custom synthesis segment growth (flagged pre-result at 35–45% YoY) — not separately disclosed in this filing; confirm on the Q2 concall
W2
Durability of the ~42.6% EBITDA margin given a ₹631 Cr inventory build this quarter — watch whether margin holds or reverts as inventory normalises
W3
Whether management revises FY27 guidance upward on the concall, given H1 EBITDA margin is already ~10pp above the 'similar to FY26' guided level
Clean quarter — no exceptional items in either Q2 FY27 or Q2 FY26 columns (the ₹74 Cr labour-code exceptional sits only in the FY26 annual column), so YoY/QoQ growth needs no adjustment; standalone and consolidated PAT growth are near-identical (63.8% vs 63.6% YoY), no material divergence.
Informational and educational content only. Not investment advice.